Targeting the deubiquitinase USP7 for degradation with PROTACs
- 13 July 2022
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (63) , 8858-8861
Abstract
A novel class of USP7 PROTACs were designed and synthesized. CST967, a CRBN-based degrader, showed potent and selective depletion of USP7 leading to apoptosis in multiple cancer lines.Keywords
All Related Versions
Funding Information
- Deutsche Forschungsgemeinschaft (Kr-3886/2-1, SFB-1074)
- The Slovenian Research and Innovation Agency (J1-2485, P1-0208)
This publication has 28 references indexed in Scilit:
- p53 stability is regulated by diverse deubiquitinating enzymesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2017
- USP7 small-molecule inhibitors interfere with ubiquitin bindingNature, 2017
- Molecular basis of USP7 inhibition by selective small-molecule inhibitorsNature, 2017
- New Modalities for Challenging Targets in Drug DiscoveryAngewandte Chemie International Edition, 2017
- Modulation of the p53/MDM2 interplay by HAUSP inhibitorsJournal of Molecular Cell Biology, 2016
- DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic TargetsFrontiers in Genetics, 2016
- Deubiquitinase inhibition as a cancer therapeutic strategyPharmacology & Therapeutics, 2015
- Regulation of proteolysis by human deubiquitinating enzymesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014
- The role of deubiquitinating enzymes in apoptosisCellular and Molecular Life Sciences, 2010
- The p53 orchestra: Mdm2 and Mdmx set the toneTrends in Cell Biology, 2010